The Distribution and Phenotypes of Blood Groups in Hematologic Malignancies.

OBJECTIVE: Blood groups are associated with duodenal ulcer, diabetes mellitus, and urinary tract infection. In some studies, a relationship was detected between hematologic and solid organ malignancies and blood groups. In this study, we investigated the frequency and phenotypes of blood groups (ABO, Kell, Duffy, Rh) in patients with hematologic malignancies. MATERIALS AND METHODS: One hundred sixty-one patients with hematologic malignancy (multiple myeloma, chronic lymphocytic leukemia, and chronic myelocytic leukemia) and 41 healthy people were evaluated prospectively. We determined phenotypes and distribution of ABO, Rh, Kell, and Duffy blood groups in all cases. Chi-square test and 1-way variance analysis were used for statistical analysis. P < .05 value was considered statistically significant. RESULTS: In patients with multiple myeloma, the A blood group was statistically significantly more frequent than in the control group (P = .021). Rh negativity was found more frequent in patients with hematologic malignancy than the control group (P = .009). Kpa and Kpb antigen positivity were found statistically significantly less frequent in patients with hematologic malignancy (P = .013, P = .007; respectively). Fy (a-b-) and K-k+ phenotypes were higher in patients with hematologic cancer than in the control group (P = .045). CONCLUSION: We determined a significant relationship between hematologic malignancies and blood group systems. In our study, due to the low number of cases and few hematological malignancy types, extensive studies with more cases and more hematologic cancer types are needed.

Serum Copper and Zinc Levels in Primary Immune Thrombocytopenia.

Although the pathogenesis of immune thrombocytopenia is not fully known, oxidative stress is one of the etiological causes. Copper and zinc are elements in the antioxidant system, and their deficiency causes oxidative stress. We aimed to determine the serum copper and zinc levels and their effects on the response to treatment in patients with immune thrombocytopenia. We analyzed 51 patients with primary immune thrombocytopenia and 33 control cases. Age, gender, and platelet values at the time of diagnosis, drugs used for the treatment of immune thrombocytopenia, remission status, and serum copper and zinc levels were recorded. The primary immune thrombocytopenia and control groups were compared in terms of serum copper and zinc levels. In addition, the relationship between the response status to the treatment of patients with immune thrombocytopenia and serum copper and zinc levels was investigated. The serum zinc level in the immune thrombocytopenia group and control group was 10.35 ± 3.28 µmol/L and 12.82 ± 2.41 µmol/L, respectively (p = 0.01). The serum copper level in patients with immune thrombocytopenia (77.3 ± 22.23 µg/dL) was significantly lower than the control group (99.4 ± 20.82 µg/dL) (p = 0.01). A significant correlation was found between the response to first-line treatment of primary immune thrombocytopenia and serum copper level (p = 0.005). The serum copper level was significantly lower in relapsed cases (p = 0.001). In conclusion, serum copper and zinc levels are lower in patients with primary immune thrombocytopenia than in healthy cases. Patients with relapsed or unresponsive to immune thrombocytopenia treatment have lower serum copper levels than other patients.

Evaluation of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in Turkey: a multicenter retrospective analysis.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare X-linked genetic disorder. On the contrary to its name, it is a multisystemic disease and various symptoms other than hemoglobinuria could be occurred. It could be life threatening especially because of thromboembolic events. In the last decade, a terminal complement inhibition with eculizumab approved with promising results for PNH patients. We conducted this study to evaluate the long term experience of eculizumab therapy from Turkey for the first time. Our cohort included 138 patients with PNH treated with eculizumab between January 2008 and December 2018 at 28 centers in Turkey. Laboratory and clinical findings at the time of diagnosis and after eculizumab therapy were recorded retrospectively. The median age was 39 (range 18-84) years and median granulocyte PNH clone size was 74% (range 3.06-99.84%) at the time of diagnosis. PNH with bone marrow failure syndrome was detected in 49 patients and the rest of 89 patients had classical PNH. Overall 45 patients (32.6%) had a history of any prior thrombotic event before eculizumab therapy and only 2 thrombotic events were reported during the study period. Most common symptoms are fatigue (75.3%), hemoglobinuria (18.1%), abdominal pain (15.2%) and dysphagia (7.9%). Although PNH is commonly related with coombs negativity, we detected coombs positivity in 2.17% of patients. Seven months after the therapy, increased hemoglobin level was seen and remarkably improvement of lactate dehydrogenase level during the treatment was occurred. In addition to previous studies, our real life data support that eculizumab is well tolerated with no serious adverse events and improves the PNH related findings.

Peritonitis incidence was correlated with duration of peritoneal dialysis rather than leptin or neutrophil to lymphocyte (n/l) ratio in peritoneal dialysis patients.

OBJECTIVE: End stage renal disease (ESRD) has a high worldwide prevalence and incidence. Peritonitis is one of the leading causes of hospitalization in peritoneal dialysis patients. Although inflammatory markers show increased inflammatory responses, cellular immune response was decreased in ESRD patients. Leptin is an adipocyte-derived hormone that has activity in energy, nutrition and immune system. Neutrophil to lymphocyte ratio (N/L) was emerged as a predictive and prognostic criterion in many instances. In this study, we aimed to investigate the relationships between increased inflammation in peritoneal dialysis patients and leptin, N/L ratio. MATERIALS AND METHODS: Forty-one ESRD patients, who were been at least 12 months of peritoneal dialysis therapy, were included in the study. Patients' demographic properties were recorded. Serum leptin level, WBC count, C-reactive protein, erythrocyte sedimentation rate and biochemical markers were measured. Patients with active viral or bacterial infection, malignancy, inflammatory disease, immunosuppressive medication users were all excluded from the study. Age and sex-matched healthy control group was included in the study only for their leptin levels. RESULTS: The measured mean serum leptin level of the patient group was statistically significantly higher than control group (1624.88±1608.16 and 416±439.85). The calculated mean peritonitis incidence was 0.041±0.047 peritonitis/per year. The number of peritonitis attack was significantly correlated with duration of peritoneal dialysis, body mass index (BMI), age and presence of cardiovascular disease. Serum leptin level was significantly correlated with sex, age, primary cause of ESRD, BMI, blood glucose level and duration of peritoneal dialysis (PD). CONCLUSION: We detected that ESRD patients have higher serum leptin levels compare to healthy adults. Increased leptin was correlated with sex, age, BMI, primary cause of ESRD and serum glucose level. Number of peritonitis attack and peritonitis incidence was significantly correlated with the duration of PD, BMI and sex. We weren't able to show the predictive N/L value in PD patients in case of peritonitis.

Acute promyelocytic leukemia, centre, experience, Turkey.

Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia (AML) and has distinct hematopathologic, cytogenetic, clinical and molecular features. This study was a retrospective review of 18 adult patients (10 male, 8 female; mean age of 32.17 ± 5.66 (15-61 years) with APL at our department from January 2006 to December 2011. Following induction therapy, 17 patients achieved CR, 1 of 18 patients died of result bleeding within thirty-sixth hours of admission. In two of 18 patients developed RAS. The relapse rate was 27% (5/18). Fourteen of 18 patients (77%) have been followed in remission. APL is a malignancy requiring quick diagnosis, efficient treatment and supportive care system. ATO, one of the important therapy option in the treatment of APL, cannot be obtained easily in developing countries. This may lead to an increase in the mortality rates. The studies should be made with more number of patients and a longer period of time for accurate results.

Low-dose cytosine arabinoside-induced syptomatic bradycardia in a patient with acute myeloid leukemia.

Cytosine arabinoside (Ara-C) is one of the critical agents for the treatment of acute myeloid leukemia (AML). The toxicity profile of Ara-C is highly dependent on the dose and schedule of administration. Cardiologic complications associated with Ara-C are rare. These side effects were reported with high doses of cytarabine (1-3 g/m2, 6-12 doses) in the literature. Herein, we report a patient who developed symptomatic sinus bradycardia while receiving low-dose Ara-C therapy for AML. A 45-year-old female patient diagnosed with AML was treated with standard remission induction chemotherapy protocol that includes 3 days of anthracycline and 7 days of low-dose (100-200 mg/m2 2-1) Ara-C. The same chemotherapy regimen was applied again on the 15th day of admission. During the second chemotherapy cycle, the patient developed symptomatic sinus bradycardia. All causes except Ara-C were excluded after required investigational procedures. Ara-C infusion was discontinued for a while and after her symptoms passed chemotherapy was completed with atropine support. Cardiac toxicity is scarce with Ara-C. We want to remind that clinicians should be aware of this potential toxic manifestation even in low doses of the medication, especially as Ara-C is widely used in the treatment of leukemia. .

Mercury toxicity: a family case report.

BACKGROUND: Environmental pollution exposes humans to toxic substances. Herein we present 5 family members aged20-54 years that were poisoned by liquid mercury. CASE REPORTS: Case 1 presented to our clinic with cough, fever, and night sweats. The patient had neutropenia, anemia,and pneumonia, rapidly developed acute respiratory distress syndrome (ARDS), and died on day 4 of hospitalization.Her WBC count was 0.4 × 10³ mm-3 (normal range: 4.3-10.3 × 103 mm-3) and Hb was 10.8 g dL-1 (normal range: 11.5-16.0 g dL-1). Case 2 presented with bicytopenia; the leukocyte count was 1.3 × 103 mm-3 (normal range: 4.3-10.3 × 103mm-3) and the PLT count was 88 × 103 mm-3 (normal range: 150-400 × 103 mm-3). Cases 2 and 3 had toxic peripheralneuropathy. The PLT count in case 3 was 123 × 103 mm-3 (normal range: 150-400 × 103 mm-3). Cases 4 and 5 presentedwith fatigue and headache; these 2 patients did not have positive findings, apart from high levels of mercury in theblood. We have written informed consent. CONCLUSION: We think that heavy metal exposure-although rare-should be considered in patients that present withnumerous symptoms involving multiple systems, including the cardiovascular, respiratory, and neurological systems.The present report is unique in that in describes mercury poisoning in 5 members of the same family.

Thrombotic thrombocytopenic purpura: A single - Centre experience.

We aimed to describe the characteristics, treatment regime, and 6-month all-cause mortality of thrombotic thrombocytopenic purpura (TTP) patients treated with total plasma exchange in the our clinic. Thirteen patients were included in the study. Mortality rates of TTP have improved over the last three decades but they are still too high according to modern therapy expectations. Etiology directed treatment should be added to total plasma exchange in secondary TTP cases. Based on TTPs' immunologic etiology, immune modulator and immune suppressor agents have been applied together with total plasma exchange, but mostly in anecdotal case reports or with questionable responses.

The Levels of Serum C-Reactive Protein, Beta 2 Microglobulin, Ferritin, Lactate Dehydrogenase and Some Specific Proteins in Patients with Non-Hodgkin's Lymphoma Before and After Treatment.

OBJECTIVE: The aim of this study was to measure serum C reactive protein, ß2 microglobulin, ferritin, lactate dehydrogenase, complement 3, complement 4, immunoglobulin A, immunoglobulin M, immunoglobulin G and transferrin levels in patients with Non-Hodgkin Lymphoma before and after treatment, and to determine whether any differences occur with treatment, investigate relationship between these parameters and systemic symptoms, and to determine whether they could be used as tumor markers. MATERIALS AND METHODS: The parameters listed above were studied before and after treatment in sera of 27 patients with the diagnosis of Non-Hodgkin Lymphoma who admitted to our department. Of the patients, 10 (37%) were females and 17 (63%) were males. Mean age was 57.7 ± 16.5 (19-82) years. The subjects were newly diagnosed and treatment. RESULTS: Post-treatment serum ferritin and CRP levels were found to be significantly decreased in patients with NHL compared to pre-treatment levels (p=0.009 and p=0.015, respectively). In addition, ferritin levels measured before treatment were significantly lower in subjects with B symptoms than those without B symptoms (p=0.02). IgA levels of patients with B symptom were significantly increased compared to those without B symptoms following treatment (p=0.03). CONCLUSIONS: We are in the opinion that serum ferritin and CRP parameters may be used as tumor markers and may be indicators in the efficacy evaluation of treatment in Non-Hodgkin's Lymphoma.

The effects of age and gender on CD3+ and CD19+ lymphocyte in gingival tissue and peripheral blood: an animal study

Aim: The aim of the present study was to determine age- and gender-related values for healthy mice of CD3+ T and CD19+ B lymphocytes and CD3+/ CD19+ (T/B) ratios in peripheral blood and gingival tissue by the flow cytometry technique. Methods: The study was carried out on periodontally healthy 60 BALB/c mice. They were divided into five groups according to the their age (newborn, weaning, puberty, adult and elder). Males and females were equally represented in each group. CD3+ and CD19+ T lymphocytes and CD3+/CD19+ ratio values in gingival tissue and peripheral blood were determined using flow cytometry in the biopsy samples. Results: There were no significant differences in the CD3+ and CD19+ lymphocytes, and CD3+/ CD19+ ratios in gingival tissue for all age groups (p>0.05). Mean relative number of peripheral blood CD3+ T lymphocyte indicated a decrease in puberty group compared to the other groups (p<0.05), while relative number of peripheral blood CD19+ B lymphocyte increased in adult and aged group. The peripheral blood CD3+/ CD19+ T/B lymphocytes ratios decreased in adult and aged group. Conclusions: The results of the present study showed that differences were present in periods of life and gender in peripheral blood of mice. Moreover,significantly differences were found between genders in gingival tissue.

The effects of age and gender on gingival tissue and peripheral blood T-lymphocyte subsets: a study in mice.

The aim of this study is to investigate the effects of age and gender on relative number of CD4+ and CD8+ T lymphocyte and CD4+/CD8+ ratios in gingival tissue and peripheral blood of periodontally healthy BALB/c mice with flow cytometric analysis. The study was carried out on periodontally healthy 60 BALB/c mice. They were separated into five groups according to the life expectancy: Group I (newborn, 1-10 days old), Group II (age at weaning, 21-28 days old), Group III (age of sexual maturity, puberty, 7-8 weeks old), Group IV (adult, 8 months old), and Group V (the aged, 14 and over). Males and females were equally represented in each group. CD4+ and CD8+ T lymphocytes and CD4+/CD8+ ratio values in gingival tissue and peripheral blood were determined using flow cytometry in the biopsy samples. The relative number of CD8+ T lymphocyte in gingival tissue was higher in puberty (p < 0.05) and the aged (p < 0.05), with more significantly difference in males (p < 0.05). The CD4+/CD8+ ratios in gingival tissue were lower in puberty group and the-aged groups compared to the other groups (p < 0.05). The peripheral blood CD4+/CD8+ ratio increased in puberty and the aged groups. These differences were more significant in females than in males (p < 0.05). There were considerable negative correlations between CD4+/CD8+ T lymphocyte ratio in gingival tissue and CD4+/CD8+ T lymphocyte ratio in peripheral blood in puberty (r = 0.647, p < 0.01) and the aged ( r = 0.599, p < 0.05). In conclusion, our data suggest that CD4+/CD8+ T lymphocyte ratios in peripheral blood increase periodontally healthy mice in puberty and the old groups, while CD4+/CD8+ T lymphocyte ratios in gingival tissue decrease in the same groups. The relative number of CD8+ T lymphocytes increases in gingival tissue in puberty and the old groups when it decreases in peripheral blood. Results from this study indicated that periodontally healthy BALB/c mice may represent important information to determine the character of an immune response in the course of a lifetime.

Association between factor V Leiden mutation and coronary artery disease in the northeast region of Turkey.

Factor V Leiden (FVL) has recently been described as a genetic factor with a propensity towards venous thromboembolism; however, it is thought to have a doubtful role in coronary artery disease (CAD). This study aimed to investigate whether FVL is one of the risk factors for CAD in north-east Turkey. Seventy-five patients with angiographically documented CAD and 78 individuals without angiographically documented CAD were studied to examine the association of the frequency of the FVL mutation with CAD and control individuals. Blood samples from the patients and controls were analyzed for the FVL mutation by DNA analysis, using the polymerase chain reaction-sequence-specific primers method. FVL mutation was found in eight of 75 (10%) patients with CAD and was totally absent in control individuals (P = 0.001). There were no significant differences in terms of diabetes mellitus, hypertension, dyslipidemia, plasma fibrinogen level, smoking, gender and family history of CAD with and without the FVL mutation in the patient group. The results of this study suggest that FVL mutation may be one of the important risk factors in developing CAD in northeast Turkey.

Thrombotic thrombocytopenic purpura in a patient with Brucella infection is highly responsive to combined plasma infusion and antimicrobial therapy.

OBJECTIVE: To report a case of brucella infection presenting with thrombotic thrombocytopenic purpura (TTP) that responded well to plasma and antimicrobial treatment infusion. CASE PRESENTATION AND INTERVENTION: A 51-year-old man with moderate confusion, depressed mood and dysarthria was admitted. He was chronically ill, with fever (38.5 degrees C), anemia, jaundice and petechial-purpuric skin lesions. Neurological examination revealed diminished consciousness with a Glasgow coma scale score of 7 and +1 neck rigidity. The hemoglobin and platelet counts were decreased and reticulocyte index, erythrocyte sedimentation rate, as well as serum lactate dehydrogenase and renal dysfunction were elevated. TTP was a possible diagnosis and the patient responded well to plasma infusion and antimicrobial treatment. CONCLUSION: This report shows that therapy of underlying infection together with plasma infusion may be a successful treatment option for brucellosis-induced TTP.

[Seroprevalence of parvovirus B19 in patients with chronic idiopathic thrombocytopenic purpura]. / Kronik idiopatik trombositopenik purpura olgularinda parvovirus B19 seroprevalansi.

Although there are several studies indicating the relationship between parvovirus B19 (PV-B19) and acute idiopathic thrombocytopenic purpura (ITP) which is a form seen frequently in children, the data are not enough in terms of chronic ITP, which is a more insidious form frequently seen in adults. The aim of this study was to investigate PV-B19 seroprevalence in adult chronic ITP cases diagnosed at the haematology clinics of Atatürk University Research Hospital in Erzurum (located in eastern Anatolia, Turkey). A total of 61 patients (38 female, 23 male; mean age: 34.4 +/- 11.2 years) and 60 healthy control subjects (30 female, 30 male; mean age: 35.6 +/- 9.6 years) were included to the study. All possible etiological agents and factors other than PV-B19 were eliminated on the basis of clinical and laboratory findings. PV-B19 antibodies were screened by ELISA method, and 73.7% (45/61) of the patients were found IgG, whereas 3.2% (2/61) were found IgM seropositive. In the control group, these rates were detected as 38.3% (23/60) and 1.6% (1/60), respectively. IgG antibodies were negative in the two patients and one control who were positive for IgM. The presence of PV-B19 DNA was investigated in all of the three IgM positive subjects, and was found positive in only one patient by real-time polymerase chain reaction (PCR). The difference between patient and control groups with regard to IgG seropositivity was found statistically significant (p < 0.01), however statistical evaluation could not be performed for IgM seropositivity because of the low number of cases. As a result although the rate of IgG positivity was found statistically higher in the ITP patients in our study, this data is inefficient for the evaluation of relationship between PV-B19 and chronic ITP, indicating the need for further studies.

Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy.

OBJECTIVES: This study described the clinical features, factors affecting the outcome of this disease, risk factors, and efficacy of ribavirin therapy for CCHF patients in Eastern Turkey. METHODS: Between 2002 and 2004, 60 cases admitted to our hospital were included in this study. The diagnosis was confirmed through detection of IgM by ELISA and/or genomic segment of virus by RT-PCR. RESULTS: In multivariate analysis, farming (OR, 11.4), living in a rural area (OR, 10.05) and being bitten by tick (OR, 6.75) were determined as risk factors for CCHF. The rates of fever during hospitalization, confusion, neck stiffness, bleeding from multiple sites, and presence of petechia/ecchymosis were higher in the patients who died than in surviving ones. Additionally, the mean values of ALT, AST, LHD, CK, PTT, INR and urea were also higher, and the mean PLT count was lower in the patients who died. Mean recovery time was shorter in the cases treated with ribavirin than those of control. But, the need for blood and blood product, mean hospitalization duration, fatality rates, and hospital expenditure values were not significantly different between the group of patients treated with ribavirin and control groups. CONCLUSIONS: In Eastern Turkey, clinical features, factors influencing outcome of the disease, and risk factors were similar to other outbreaks of CCHF. Further studies are needed for the evaluation of ribavirin therapy in CCHF.

Plasma values of oxidants and antioxidants in acute brain hemorrhage: role of free radicals in the development of brain injury.

The levels of oxidants xanthine oxidase (XO), nitric oxide (NO), and malondialdehyde (MDA) and of the antioxidant enzymes superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and glutathione reductase (GRD) were determined in plasma within 24 h after onset of hemorrhagic stroke in 17 patients (9 men and 8 women, aged 60.7+/-11.5 yr) and in 20 healthy controls (12 men and 8 women, aged 62.5+/-8.3 yr). Compared to controls, the plasma SOD and total superoxide scavenger activities (TSSA) were significantly lower and the NO levels were significantly higher among the stroke patients. XO showed a slight, nonsignificant increase in the patients, but the levels of MDA, NSSA, GRD, and GSH-Px did not show any significant differences between the two groups. The hemorrhage volume was negatively correlated with the initial score of the Glasgow Coma Scale and a positive correlation with lethal outcome, but it did not correlate significantly with any of the measured parameters. The results suggest that free radicals might play a role in the development of brain injury following brain hemorrhage.

Vascular endothelial and basic fibroblast growth factor serum levels in patients with Behçet's disease.

Behçet's disease (BD) is a systemic vasculitis of unknown aetiology. Its pathogenesis is related to endothelial cell dysfunction, humoral immune defects, and immune system dysregulation. The aim of this study was to investigate the possible role of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in the pathogenesis of BD. We also investigated whether disease activity, age, or duration of BD correlates with VEGF and bFGF. We studied 33 patients and 20 healthy controls. Vascular endothelial growth factor and bFGF serum levels were measured by enzyme-linked immunosorbent assay. We measured acute phase reactants, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). The mean serum VEGF level was significantly higher in patients with BD (398.8+/-222.2 pg/ml) than the control group (193.0+/-122.4 pg/ml) (P=0.002). The levels were similar in both active and inactive BD (P=0.675) but did not correlate with disease duration, CRP, ESR, or age (P>0.05 for each). The bFGF was below detection limits in 18 of 33 patients with BD and ten of 20 controls, and its mean serum level was higher in BD patients (42.4+/-76.9 pg/ml) than controls (29.0+/-9.1 pg/ml), but this difference was not statistically significant (P=0.232). The bFGF levels were similar in both active and inactive BD (P=0.09) and, in patients, correlated with disease duration and CRP (r=0.58, P=0.02; r=-0.57, P=0.02, respectively) but not with ESR or age (P>0.05 for each). Vascular endothelial growth factor may be more important in the pathogenesis of BD than bFGF. Neither growth factor is an activity criterion or inflammatory marker in BD.

Zinc sulfate in the prevention of total-body irradiation-induced early hematopoietic toxicity: a controlled study in a rat model.

Exposure to ionizing total-body radiation suppresses hematopoiesis, resulting in decreased production of blood cells. Many researchers have demonstrated the critical role of zinc (Zn) in diverse physiological processes, such as growth and development, maintenance and priming of the immune system, and tissue repair. The aim of the present study was to determine the effects of zinc sulfate (40 mg/kg and 80 mg/kg) on early hematopoietic toxicity, caused by total-body irradiation (TBI) of rats with a single dose of 8 Gy. Both in the Zn 40 and in the Zn 80 groups, there were significantly increased white blood cell (WBC) count, when compared with control group. The WBC count was higher in the control group than in the TBI group. This result was statistically significant (p<0.05). Both the TBI+Zn 40 and the TBI+Zn 80 groups had a significantly protected WBC count against TBI. No difference was detected in any final measurement of thrombocyte count and hemoglobin level with direct comparison among all groups, with the exception that the hemoglobin level in the Zn 80 group compared to the control group. Whereas hemoglobin level in the control group was at a median figure of 13.98 g/dL (13.30-14.80), it was at a median figure of 14.25 g/dL (14.10-15.50) in the Zn 80 group. It would be worthwhile studying the effect of oral zinc sulfate supplements in radiation-treated cancer patients, in the hope of reducing radiation-induced toxicity.

Iatrogenic Kaposi 's Sarcoma.

The development of Kaposi's sarcoma (KS) has been associated with either iatrogenic or underlying disease related immunodeficiency. We report a case with iatrogenic Kaposi's sarcoma developed after treatment of non- Hodgkin's lymphoma (NHL) who was achieved partial clinical remission with systemic chemotherapy.